

Philip Barter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10486814/publications.pdf>

Version: 2024-02-01

49
papers

15,123
citations

101543

36
h-index

197818

49
g-index

51
all docs

51
docs citations

51
times ranked

18003
citing authors

#	ARTICLE	IF	CITATIONS
1	Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2005, 352, 1425-1435.	27.0	3,152
2	New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. <i>Nature Genetics</i> , 2010, 42, 105-116.	21.4	1,982
3	HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2007, 357, 1301-1310.	27.0	1,390
4	Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2556.	7.4	1,197
5	Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. <i>Nature Reviews Endocrinology</i> , 2020, 16, 177-189.	9.6	790
6	Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2010, 363, 2406-2415.	27.0	697
7	Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 715-725.	11.4	687
8	International Day for the Evaluation of Abdominal Obesity (IDEA). <i>Circulation</i> , 2007, 116, 1942-1951.	1.6	599
9	Dysfunctional HDL and atherosclerotic cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2016, 13, 48-60.	13.7	547
10	Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study. <i>Diabetes Care</i> , 2006, 29, 1220-1226.	8.6	493
11	Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment. <i>Circulation</i> , 2008, 117, 3002-3009.	1.6	405
12	Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. <i>Lancet</i> , 2006, 368, 919-928.	13.7	369
13	Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1535-1545.	2.8	305
14	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. <i>Journal of Clinical Lipidology</i> , 2014, 8, 29-60.	1.5	289
15	The emerging role of HDL in glucose metabolism. <i>Nature Reviews Endocrinology</i> , 2012, 8, 237-245.	9.6	214
16	A Genome-Wide Association Search for Type 2 Diabetes Genes in African Americans. <i>PLoS ONE</i> , 2012, 7, e29202.	2.5	197
17	Translation of High-Density Lipoprotein Function Into Clinical Practice. <i>Circulation</i> , 2013, 128, 1256-1267.	1.6	197
18	Residual macrovascular risk in 2013: what have we learned?. <i>Cardiovascular Diabetology</i> , 2014, 13, 26.	6.8	149

#	ARTICLE	IF	CITATIONS
19	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. <i>Circulation</i> , 2018, 138, 770-781.	1.6	126
20	National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. <i>Heart Lung and Circulation</i> , 2005, 14, 275-291.	0.4	115
21	Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1938-1943.	2.8	87
22	HDL-C: Role as a risk modifier. <i>Atherosclerosis Supplements</i> , 2011, 12, 267-270.	1.2	87
23	Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial. <i>American Journal of Cardiology</i> , 2009, 104, 10E-15E.	1.6	86
24	Design of the DEFINE trial: Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib. <i>American Heart Journal</i> , 2009, 158, 513-519.e3.	2.7	85
25	Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2014, 113, 76-83.	1.6	78
26	Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1793-1799.	2.8	63
27	Evaluating the Incremental Benefits of Raising High-Density Lipoprotein Cholesterol Levels During Lipid Therapy After Adjustment for the Reductions in Other Blood Lipid Levels. <i>Archives of Internal Medicine</i> , 2009, 169, 1775-80.	3.8	61
28	Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. <i>Journal of Lipid Research</i> , 2013, 54, 467-472.	4.2	52
29	Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 404-423.	2.8	48
30	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. <i>Journal of Clinical Lipidology</i> , 2018, 12, 130-136.	1.5	44
31	Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Current Medical Research and Opinion, 2011, 27, 1119-1129.	1.9	43
32	HDL cholesterol and ASCVD risk stratification: A debate. <i>Atherosclerosis</i> , 2019, 283, 7-12.	0.8	43
33	Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 543-549.	2.0	41
34	Antioxidant Effects of Statins in the Management of Cardiometabolic Disorders. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 997-1010.	2.0	39
35	Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers. <i>PLoS ONE</i> , 2014, 9, e114519.	2.5	38
36	Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 904-914.	3.4	37

#	ARTICLE	IF	CITATIONS
37	Dyslipidaemia in the Middle East: Current status and a call for action. <i>Atherosclerosis</i> , 2016, 252, 182-187.	0.8	37
38	Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East. <i>International Journal of General Medicine</i> , 2018, Volume 11, 313-322.	1.8	33
39	Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL). <i>American Journal of Cardiology</i> , 2014, 113, 1378-1382.	1.6	27
40	Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?. <i>Trends in Pharmacological Sciences</i> , 2011, 32, 694-699.	8.7	24
41	Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Tj ETQq1 1 0.784314 rgBT /Over 2015, 9, 65-71.	1.5	24
42	The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 51-57.	5.1	21
43	Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region. <i>Lipids in Health and Disease</i> , 2021, 20, 33.	3.0	20
44	Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: What we know and don't know. <i>Diabetes Research and Clinical Practice</i> , 2011, 94, 1-13.	2.8	17
45	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East. <i>International Journal of Cardiology</i> , 2016, 225, 268-283.	1.7	17
46	Introduction. <i>Atherosclerosis Supplements</i> , 2011, 12, 265-266.	1.2	8
47	Are we lowering LDL cholesterol sufficiently?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 290-291.	3.3	7
48	Evolving Targets of Therapy. , 2009, , 387-395.		0
49	Lipid management after a coronary event. , 2011, , 328-337.		0